KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Cle

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

Related Keywords

, Advanced Renal Cell Carcinoma , Lenvatinib Plus Pembrolizumab , Clear Cell , Renal Cell Carcinoma , Nrcc , Advanced Rcc , Non Clear Cell Rcc , Non Clear Cell Renal Carcinoma , Lenvatinib , Pembrolizumab , Keynote B61 ,